Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + Dapagliflozin vs Insulin Glargine in T2DM
NCT02551874Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of saxagliptin, dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2015; status: completed.
02
Drugs
saxagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02551874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551874.